Naval Daver, MD

An oncologist discusses the future of myelodysplastic syndrome, including upcoming studies and potential treatments.

Dr. Naval Daver provides insight on the emerging first-line treatment options for high-risk myelodysplastic syndrome and breaks down clinical trial data.

An expert details the treatment options for high-risk myelodysplastic syndrome.

Naval Daver, MD, illustrates the goals of treatment and treatment options for low-risk myelodysplastic syndrome.

A key opinion leader describes how myelodysplastic syndrome is diagnosed, the typical presenting symptoms, and the methods of risk assessment.

Naval Daver, MD, explains myelodysplastic syndrome, including risk factors and potential complications.

Naval Daver, MD, explains the rationale for the phase II QUAZAR trial, which assessed the efficacy and safety of azacitidine in patients with acute myeloid leukemia.

Naval Daver, MD, assistant professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses agents being investigated in acute myeloid leukemia (AML).